...
首页> 外文期刊>ChemMedChem >Structural Model for the Binding Sites of Allosterlcally Potentiating LIgands on Nicotinic Acetylcholine Receptors
【24h】

Structural Model for the Binding Sites of Allosterlcally Potentiating LIgands on Nicotinic Acetylcholine Receptors

机译:烟碱乙酰胆碱受体上的变构增强配体结合位点的结构模型。

获取原文
获取原文并翻译 | 示例

摘要

Current treatments of Alzheimer's disease include the allosteric potentiation of nicotinic acetylcholine receptor (nAChR) response. The location of the binding site for allosteric potentiating ligands (APLs) within the receptor is not yet fully understood. Based on homology models for the ligand binding domain of human a7, human a4|32, and chicken a7 receptors, as well as blind docking experiments with galanthamine, phys-ostigmine, codeine, and 5HT, we identified T197 as an essential element of the APL binding site at the outer surface of the ligand binding domain (LBD) of nAChR. We also found the previously known galanthamine binding site in the region of K123 at the inside of the receptor funnel, which, however, was shown to not be part of the APL site. Our results are verified by site-directed mutagenesis and electrophysiological experiments, and suggest that APL and ACh bind to different sites on nicotinic receptors and that allosteric potentiation may arise from a direct interplay between both these sites.
机译:阿尔茨海默氏病的当前治疗方法包括烟碱乙酰胆碱受体(nAChR)反应的变构增强作用。受体内变构增强配体(APL)的结合位点的位置尚未完全了解。根据人a7,人a4 | 32和鸡a7受体配体结合域的同源性模型,以及加兰他敏,phys-ostigmine,可待因和5HT的盲对接实验,我们确定T197是其中的必需成分。 nAChR的配体结合域(LBD)外表面的APL结合位点。我们还在受体漏斗内部的K123区域中发现了先前已知的加兰他敏结合位点,但事实证明,该结合位点不是APL位点的一部分。我们的结果通过定点诱变和电生理实验得到验证,并表明APL和ACh结合到烟碱样受体上的不同位点,并且变构作用增强可能源于这两个位点之间的直接相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号